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ABSTRACT
Objective: This review will summarize pharmacogenetic studies of single nucleotide polymorphisms in genes coding enzymes of methotrexate (MTX) 
pathway, related to its response and toxicity in rheumatoid arthritis (RA). In addition, this review focuses on the racial and ethnic differences in 
distribution of the polymorphisms in genes related to efficacy and toxicity of MTX in RA.
Methods: Articles were searched using Pubmed database using the search term “pharmacogenetics and MTX and arthritis.” The search revealed 72 
articles, of which 27 were given special importance, due to open-access.
Results: Many genes and single nucleotide polymorphisms are investigated in this context, and the highlighting genes are ATP-binding cassette 
proteins (ABCB1) reduced folate carrier (RFC), methylenetetrahydrofolatereductase (MTHFR), gamma-glutamyl hydrolase (GGH), serine hydroxyl 
methyltransferase (SHMT), 5-aminoimidazole-4-carboxamide ribonucleotidetransformylase (ATIC), methionine synthase reductase (MTRR), 
methionine synthase (MS), adenosine monophosphate deaminase1 (AMPD1), inosine triphosphate pyrophosphatase (ITPA). The study highlighted 
RFC-1 80AA, ITPA 94CC, and AMPD1 347CC as responders. The allelic types prone to toxicity were MTHFR 677TT, MTRR 2756AA, MS 66GG, SHMT 
1420CC, ATIC 347GG, and thymidylate synthase *3/*2. The genotypes reported as non-responders were ABCB1 3434TT, MTHFR 1298AA, DHFR 
A317G, GGH 16CC, and GGH 401TT.
Conclusion: Although these studies highlight inconsistency in results, due to the difference in sample size and assessment parameters and racial and 
ethnic differences, larger prospective studies are essential to reach the cornerstone of the concept of personalized medicine.
Keywords: Arthritis, Gene, Methotrexate, Pharmacogenetics, Rheumatoid.
INTRODUCTION
Methotrexate (MTX) is the cornerstone for the therapy of rheumatoid 
arthritis (RA) in spite of the advent of newer biologics. MTX is fast 
acting and has the best efficacy:toxicity ratio and also cheaper. For the 
treatment of RA, it was first introduced in 1951, but after 30 years, only 
widespread use in RA came into force in 1985. It is used at the dose of 
5–25 mg/week in the treatment of RA and the dose for its anticancer 
effect is 5000 mg/week. As a gold standard, it is started as monotherapy, 
and a low dose is safe and well-tolerated. For patients unresponsive to 
nonsteroidal anti-inflammatory drugs, it is still the first-line drug for 
therapy in RA [1].
MTX is taken up by the cells glutamated by foly-poly glutamyl 
synthase (FPGS) and there is a competition by gamma-glutamyl 
hydrolase (GGH), which deconjugates the drug and the free drug is 
effluxed by ATP-binding cassette (ABC) proteins. Polyglutamation 
up to 7 subunits takes place and MTX-polyglutamates (MTX-PG5-7) 
roughly correlate with the therapeutic efficacy of the drug. Free MTX 
is eliminated within 24 h, and a small portion of it is metabolized in 
the liver to 7-hydroxy MTX. At cellular level, MTX and MTX-PGs inhibit 
several enzymes of purine and pyrimidine biosynthesis and also exert 
an anti-inflammatory effect. Methotrexate inhibits several enzymes 
of cell proliferation such as dihydrofolate reductase (DHFR), involved 
in DNA biosynthesis, thymidylate synthase (TYMS), involved in 
DNA biosynthesis and repair and 5-aminoimidazole-4-carboxamide 
ribonucleotide (AICAR), contributing to anti-inflammatory and 
antiproliferative effects of accrued adenosine. The other enzymes 
inhibited by the drug are homocysteine pathway enzymes such 
as methylenetetrahydrofolate reductase (MTHFR), methionine 
synthase reductase (MTRR), and methionine synthase (MS), which 
could lead to accumulation of homocysteine and related adverse 
effects [2]. Due to variation in response and toxicity profile, one-third 
of the patients discontinue therapy due to its adverse effects. Folate 
antagonism leads to anemia, stomatitis, oral ulcers, and elevation 
of transaminases in the liver, which could be alleviated by the 
administration of folic or folinic acid. Accumulation of adenosine also 
leads to gastrointestinal (GI) adverse events (AEs). The uncommon 
toxicities are nodulosis, hepatic fibrosis, pulmonary fibrosis, and 
renal insufficiency [3]. Due to these factors, it is essential to predict 
the efficacy and adverse effects before administration, to effectively 
use the drug in the treatment of RA. Since the drug is excreted within 
24 h and measurement of MTX-PGs routinely in clinical practice is 
not feasible, pharmacogenetics could be a useful tool to monitor the 
treatment outcomes.
Pharmacogenetics is advancing area of research, and the data are of 
value in tailoring therapy according to individual’s genotype profile. 
Single nucleotide polymorphisms (SNPs) are good markers of genetic 
variation and the frequency of these SNPs among different races and 
ethnicities. In the case of multiple SNPs in a gene, it is appropriate 
for haplotype analysis. There are several reports on the association 
between genetic polymorphisms in metabolic enzymes and efficacy or 
adverse effects of MTX.
The purpose of this review is to determine the role of polymorphisms 
influencing therapeutic efficacy and toxicity of MTX in RA, from 
published studies.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i8.24563
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PHARMACOGENETICS OF MTX
Genetic polymorphism related to efflux of MTX
ABC proteins (ABCB1) C3435T
This is one of the important genes related to P-gp expression, which 
are best drug transporters in humans. There are several genes and 
several polymorphisms related to multiple drug resistance, and ABCB1 
C3435T is widely studied in RA patients and this gene is otherwise 
called as MDR1 gene. This mutation is a synonymous mutation that 
occurs in chromosome 1, and the reference SNP (rs) assessed is 
rs1045642, which increases the efflux of xenobiotics out of the cells 
(Table 1).
Four relevant studies were analyzed in relation to response to MTX and 
susceptibility to its toxicity. Two studies in Japanese RA patients and 
one Polish study reflected the influence of this SNP to the sensitivity 
of MTX as therapeutic response. It was found that only one Indian 
study was performed in this context. In India, the association of 
this polymorphism was studied in the treatment of lung cancer [4], 
epilepsy [5], and acute leukemia [6].
In healthy individuals, the distribution of the different alleles of this 
polymorphism was similar in Indians and Polish but was significantly 
different when compared to Japanese (Table 2). In Polish RA patients, 
3435TT genotypes were found to be good responders, whereas 
contradictory reports were observed in Japanese patients [7,8]. In 
Japanese studies, one reported them as responders and other reported 
them as non-responders [8,9]. In Indian study, the 3435CT genotypes 
were found to be non-responders [10] and Grabar et al. reported 
that 3435T allele carriers have the risk of adverse effects to MTX, in 
Yugoslavian RA patients [11] (Table 3).
Genetic polymorphism related to influx of MTX
Reduced folate carrier-1 (RFC-1) G80A
RFC is an anion exchanger, a transmembrane protein comprising 591 
amino acids, and transfers folates across the cell membrane. This 
polymorphism is otherwise called as solute carrier, SLC19A1 G80A. RFC 
influences the entry of MTX into the cells, and the carriers of AA alleles 
had increased MTX levels than GG or AG alleles, by increased uptake in 
B and CD4+ cells, and this polymorphism is relevant for deciding the 
dosage of MTX in autoimmune disorders [12].
This mutation is a missense mutation that occurs in chromosome 21 
and the reference SNP assessed is rs1051266, which increases the 
efflux of xenobiotics out of the cells. The amino acid change that occurs 
is histidine to arginine, and this leads to decreased influx of MTX into 
the cells (Table 1).
The allelic distribution of this SNP is significantly different in Indian 
population when compared to Japanese healthy volunteers (Table 2).
Very few Indian studies were related to this polymorphism, and 
they were studied in malaria [13], childhood acute lymphoblastic 
leukemia [14], and breast cancer [15]. The distribution of the allelic 
Table 1: Genetic polymorphisms of methotrexate in different enzymatic pathways
Gene Nucleotide sequence Consequence Amino acid substitution Location dbSNP Effect 
ABCB1 C3435T Synonymous No amino acid substitution Chr.7 rs1045642 Increased MTX efflux from the cells 
RFC1 G80A Missense Histidine to arginine Chr.21 rs1051266 Decreased MTX entry into cells
MTHFR C677T Intergenic Alanine to valine Chr.1 rs1801133 Decreased enzyme activity
MTHFR A1298C Missense Glutamine to alanine Chr.1 rs1801131 Decreased enzyme activity
GGH C401T Missense Threonine to isoleucine Chr.8 rs11545078 Increased deconjugation of MTX
SHMT C1420T Intronic No amino acid substitution Chr.17 rs9901160 Decreased enzyme activity
ATIC C347G Missense Threonine to serine Chr.2 rs2372536 Decreased enzyme activity
MTRR A2756G Missense Aspartate to glycine Chr.1 rs1805087 Decreased enzyme activity
MS A66G Missense Isoleucine to methionine Chr.1 rs1801394 Decreased enzyme activity
AMPD1 C34T Stop gained Glutamine to lysine Chr.1 rs17602729 Decreased enzyme activity
ITPA C94A Missense Proline to threonine Chr.1 rs1127354 Decreased enzyme activity
ABCB1: ATP-binding cassette proteins, MTX: Methotrexate, Chr: Chromosome number, dbSNP: Databse of single nucleotide polymorphisms, RFC: Reduced folate carrier, 
MTHFR: Methylenetetrahydrofolate reductase, GGH: Gamma-glutamyl hydrolase, SHMT: Serine hydroxyl methyltransferase, ATIC: 5-aminoimidazole-4-carboxamide 
ribonucleotidetransformylase, MTRR: Methionine synthase reductase, MS: Methionine synthase, AMPD1: Adenosine monophosphate deaminase1, ITPA: Inosine 
triphosphate pyrophosphatase
Table 2: Allelic distribution of different SNPs of methotrexate genes in different population
Gene Healthy individuals Chi-square p value Rheumatoid arthritis PMID
ABCB1 C3435T N CC CT TT CC CT TT
Indians 249 19.7 51.4 28.9 No relevant data [6]
Japanese 188 31.4 52.2 16.4 6.1329 <0.046 159 34 51.6 14.4 [16]
Polish 97 26.9 53.8 18.3 3.6978 NS No relevant data [7]
RFC-1 G80A GG GA AA GG GA AA
Indians 173 0.06 60.6 33.5 No relevant data [13]
Japanese 299 17.4 51.8 30.8 15.0021 <0.0005 159 21.4 46.5 32.1 [16]
MTHFR C677T CC CT TT CC CT TT
Indians 173 73.4 24.8 0.02 No relevant data [13]
African-Americans 53 75 23 2 0.4387 NS 138 79 20 1 [30]
Caucasians 50 50 44 6 13.0994 <0.001 393 50 40 10 [30]
MTHFR A1298C AA AC CC AA AC CC
Indians 140 45.7 52.9 1.40 No relevant data [47]
African-Americans 53 38 30 2 10.9524 <0.004 138 74 25 1 [30]
Caucasians 50 50 38 12 11.9469 <0.002 393 45 42 13 [30]
Japanese 299 68.9 28.1 3 13.316 <0.001 159 68.6 26.4 5 [16]
ABCB1: ATP-binding cassette proteins, MTX: Methotrexate, Chr: Chromosome number, dbSNP: Databse of single nucleotide polymorphisms, RFC: Reduced folate carrier, 
MTHFR: Methylenetetrahydrofolate reductase, SNPs: Single nucleotide polymorphisms
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Table 3: Genetic polymorphisms of methotrexate and their relation to its efficacy and toxicity in rheumatoid arthritis
Genetic studies in different population MTX efficacy MTX toxicity Reference
ABCB1 C3435T
Japanese 124 3435TT nonresponders [8]
Japanese 55 3435TT responders [9]
Polish 255 3435TT responders [7]
Indians NA 3435CT nonresponders [10]
Yugoslavia 213 3435T is a risk genotype
RFC-1 G80A N
Americans 226 80AA responders [2]
Polish 174 80AA responders [17]
Japanese 81 80AA responders [18]
Indians 322 80AA responders [19]
Yugoslavia 213 80G allele is a risk genotype [11]
MTHFR C677T
Dutch 236 677TT hepatic AE [23]
Japanese 106 677TT hepatic AE [24]
Japanese 186  677TT hepatic AE [25]
Americans 214 677TT CNS adverse effects [26]
Americans 71 677TT risk genotypes for osteoporosis/osteopenia [27]
Indians 322 677CC responders [19]
MTHFR A1298C [11]
Dutch 205 1298AA responders 1298CC (GI AE) [29]
Japanese 106 1298CC responders [24]
Japanese 186 1298CC responders [25]
Japanese 55 1298AA responders [9]
Americans 223 1298AA (Indigestion) [30]
Americans 48 1298CC (GI AE, Neurologic AE) [29]
Americans 319 1298AC/CC risk genotypes [31]
Israelis 93 1298CC responders 1298AA higher homocysteine levels [32]
Indians 322 1298AA responders [19]
Yugoslavia 213 1298CC alleles had lesser adverse effects [11]
Koreans 167 1298CC allele is a risk genotype [33]
GGH C401T
Indians 322 401TT hepatic AE [19]
SHMT C1420T
Americans 214 1420CC alopecia AE [26]
Indians 322 1420CC GI AE [19]
ABCB1: ATP-binding cassette proteins, MTX: Methotrexate, RFC: Reduced folate carrier, MTHFR: Methylenetetrahydrofolate reductase, GGH: Gamma-glutamyl hydrolase, 
SHMT: Serine hydroxyl methyl transferase
variants significantly differed when compared to Japanese healthy 
individuals [13,16].
Dervieux et al. investigated the effects of this polymorphism in American 
RA patients and reported that carriers of 80AA genotype have higher 
MTX-PG levels and thus influence polyglutamation and found to be good 
responders to MTX therapy [2]. Drozdzik et al. also reported that the 
remission in Polish RA patients is increased when they have the 80AA 
genotype [17]. Hayashi et al. also reported that the same and AA allele 
genotypes had increased intracellular MTX uptake and increased efficacy 
and the need for a combination with biologics is less and insisted that 
this polymorphism influences MTX efficacy in Japanese RA patients [18], 
and Ghodke et al. also reported the same in Indian RA patients [19] and 
Grabar et al. reported that 80 G allele carriers have the risk of adverse 
effects to MTX, in Yugoslavian RA patients [20] (Table 3).
Genes related to metabolic pathway of MTX
MTHFR
This gene encodes an enzyme that catalyzes the reduction of 5, 
10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a carbon donor 
in the metabolism of folate to methionine, and the polymorphism led to a 
reduction in enzyme activity and associated with hyperhomocysteinemia. 
There were about dozen polymorphisms in this gene; it was identified that 
MTHFR C677T and A1298C were the widely studied gene polymorphisms.
This polymorphism C677T was first reported by Frosst et al. in 1995 [21] 
and the second polymorphism A1298C was reported by Weisberg et al. 
in 1998 [22]. In C677T, heterozygous mutants have ~40% reduction 
in enzyme activity and homozygous mutants have ~70% reduction, 
and this leads to thermolabile variant of the enzyme. In A1298C 
polymorphism, the homozygous mutants have about ~40% reduction 
in enzyme activity.
The first article related to this polymorphism C677T was published by 
van Ede et al. which assessed discontinuation of MTX due to an elevation 
of transaminases. In this study, it was concluded that TT genotypes were 
found to be the risk genotypes. The elevation of liver enzymes is due to 
increased homocysteine levels, and supplementation with folic acid or 
folinic acid reduced the toxicity-related discontinuation rates [23].
MTHFR C677T
This mutation is a missense mutation located in chromosome 1 and 
the reference SNP (rs) assessed is rs1801133, and the change in amino 
acid sequence occurs as valine instead of alanine and leads to defective 
enzyme activity (Table 1).
The allelic distribution of the different genotypes of this polymorphism 
is similar in Indians and Afro-Americans but significantly different from 
Caucasian healthy population (Table 2).
van Ede et al. reported that the presence of 677CT or 677TT genotypes 
in Dutch RA patients has led to discontinuation of MTX therapy 
due to the risk of adverse effects and the presence of this mutation 
increased the liver toxicity. The presence of defective enzyme leads to 
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hyperhomocysteinemia, and elevation of alanine aminotransferase and 
supplementation of folic or folinic acid could prevent these adverse 
effects [23].
Urano et al. reported that, in Japanese RA patients, the presence of 677C 
allele leads to good response and presence of 677T allele increases the 
adverse effects [24]. Taniguchi et al. also proved that 677TT genotypes 
were prone to adverse effects of MTX [25].
Weisman et al. studied the effect of this polymorphism in American 
RA patients and reported that 677TT genotypes are prone to the 
risk of central nervous system (CNS) adverse effects [26]. Brambila-
Tapia et al. studied this MTHFR C677T in American RA patients and 
carriers of T alleles (TT homozygotes) had lower BMD and reported to 
have increased risk of osteoporosis, and folic acid supplementation is 
suggested as a prophylactic measure [27].
Ghodke et al. reported that 677TT genotypes are susceptible to adverse 
effects of MTX [19]. In another Indian study by Aggarwal et al., it was 
concluded that this polymorphism was not related to efficacy or toxicity 
of MTX [28].
MTHFR A1298C
This mutation is a missense mutation located in chromosome 1 and the 
reference SNP (rs) assessed is rs1801131; the change in amino acid 
sequence occurs as glutamine instead of alanine and leads to defective 
enzyme activity (Table 1).
This mutation is a missense mutation located in chromosome 1 and the 
reference SNP (rs) assessed is rs1801131; the change in amino acid 
sequence occurs as alanine instead of glutamine and leads to defective 
enzyme activity (Table 1).
The allelic distribution of the different genotypes of this polymorphism is 
significantly different in Afro-Americans, Caucasians, and Japanese healthy 
population when compared to Indian healthy population (Table 2).
Wessels et al. reported that MTHFR 1298AA was found to be responders 
and has improvement in the clinical indices and also concluded that C 
allele is also susceptible to adverse effects of MTX [29].
Urano et al. reported that, in Japanese RA patients, 1298C allele carriers 
were found to be good responders and they received lower doses of 
MTX to attain remission [24]. A similar result was reported by Taniguchi 
et al. in Japanese RA patients, the 1298CC genotypes were found to be 
good responders to MTX, and they were found to receive lower doses 
of MTX in a year of its therapy [25]. Kato et al. studied the effect of 
A1298C in Japanese RA patients and reported that AA genotypes were 
associated with good response, which is contradictory to previous 
studies in Japanese RA patients [9].
Hughes et al. found that, in American RA patients, the carriers of 1298A 
allele were susceptible to adverse effects of MTX that too in Caucasians. 
The reported adverse effects were indigestion due to GI disturbances 
caused by MTX [30].
Dervieux et al. reported that the carriers of C allele in American RA 
patients and adverse effects of GI and CNS were probable and 1298AC/
CC genotypes were risk genotypes [2].
Davis et al. found that A1298C polymorphism was associated with 
adverse effects and increased copies of this lead to a higher incidence of 
adverse effects in American RA patients [31].
Berkun et al. reported that the allele frequency of 1298CC was higher 
in Israeli RA population and the carriers of 1298AA allele had a higher 
frequency of adverse effects, such as hyperhomocysteinemia in spite 
of higher folic acid supplementation, and 1298CC may protect against 
MTX-related adverse effects [32].
Grabar et al. reported that MTHFR A1298C polymorphism is protective 
related to adverse effects of MTX, in Yugoslavian RA patients [20].
Choe et al. investigated the C677T polymorphism in Korean RA patients 
and found 1298AC/CC genotypes experienced at least one adverse 
effect of MTX when compared to 1298AA genotypes [33].
Haplotype analysis
The MTHFR is a gene with two SNPs related to RA, and some studies 
were performed based on haplotype analysis of MTHFR C677T and 
A1298C. In Japanese RA patients, it was reported that carriers of 
677T-1298A were found to have a higher frequency of adverse effects 
and carriers of 677C-1298C were found to receive lower MTX doses and 
are good responders [24].
Serine hydroxyl methyltransferase (SHMT C1420T)
It is an important enzyme in one-carbon pathway of the purine and 
thymidylate biosynthesis, leading to DNA synthesis.
This mutation is a intronic mutation located in chromosome 17 and the 
reference SNP assessed is rs9901160; no amino acid substitution takes 
place but could decrease the enzyme activity (Table 1).
Very few studies were performed in RA patients, and an Indian 
study [19] highlighted that GI adverse effects are common in CC allelic 
genotypes and the same was reported in American patients [26]. Other 
Indian studies reflected investigation of this polymorphism in breast 
cancer [34] and autism [35] (Table 3).
DHFR
This is a key enzyme inhibited by MTX and polymorphisms in it are less 
studied (Fig. 1). It has reported polymorphisms such as rs12517451, 
rs10072026, and rs1643657, associated with adverse effects [36]. DHFR 
A317G was studied by Milic et al. and found that 317AA genotypes were 
associated with poor response [37].
Genetic polymorphism related to polyglutamation
GGH
GGH is a lysosomal peptidase that catalyzes elimination of gamma-linked 
polyglutamates. Long-chain MTX-PGs are converted to short-chain MTX-
PGs and further converted back to MTX and efflux from the cell. Since the 
MTX-PGs are associated with disease activity in RA, GGH polymorphisms 
could influence the therapeutic outcome. Three polymorphisms had been 
widely studied, and they are GGH C401T, GGH C452T, and GGH T16C.
This mutation is a missense mutation located in chromosome 8 
and the reference SNP assessed is rs11545078, which increases the 
deconjugation of MTX, which is effluxed out of the cells. The amino acid 
change that occurs is threonine to isoleucine, and this leads to increased 
efflux of MTX into the cells (Table 1).
Chave et al. studied the expression of this polymorphisms and its 
functional activity in MCF-7 cells and reported that increased 
expression could progress as resistance to MTX [38]. Ghodke et al. 
reported that TT allelic genotypes in Indian RA patients were 
found to be more susceptible to hepatic adverse effects of MTX [19] 
(Table 3).
FPGS
This gene is related to polyglutamation of MTX and is important in one-
carbon metabolism. In a study by Oppeneer et al., they found that this 
gene is not associated with homocysteine metabolism [39]. Sharma et al. 
reported that a polymorphism in this gene (rs1544105) is associated 
with poor response to MTX therapy in RA [40]. In UK rheumatoid 
cohort study by Owen et al., they found that FPGS polymorphism was 
associated with adverse effects [36].
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Genes related to pyrimidine pathway
TYMS or TSER *2/*3
Dervieux et al. assessed this polymorphism and concluded that patients 
having two tandem repeats had better clinical response than triple 
repeat [2]. Kumagai et al. assessed the impact of this polymorphism 
in Japanese RA patients and found that triple-repeat allele of the 
polymorphism (*3/*3) received a higher dose of MTX than double 
repeat allele [41].
TYMS or TSER 3’UTR 6 bp deletion TTAAAG
Kumagai et al. studied this polymorphism in Japanese RA patients 
and had shown that this 6 bp deletion leads to decrease in CRP levels 
and improvement in response [36]. This deletion polymorphism is 
associated with decreased expression of mRNA and could increase the 
drug response in RA patients [37].
TYMS or TSER (rs2853539)
Sharma et al. studied the effect of this polymorphism in RA patients and 
found that carriers of AA genotype are non-responders [40].
Genes related to adenosine pathway
Blockade of AICAR affects purine synthesis and leads to accumulation 
of adenosine, and the anti-inflammatory effects of MTX are mediated 
through this pathway. The polymorphisms in genes influencing anti-
inflammatory adenosine release are 5-aminoimidazole-4-carboxamide 
ribonucleotide transformylase (ATIC) C347G, inosine triphosphate 
pyrophosphatase (ITPA) C94A, and AMPD1 C34T and adenosine 
receptors (ADORA) 2a. MTX inhibits the deamination of adenosine 
and modulates its pharmacokinetics and pharmacodynamics. 
Adenosine exhibits its anti-inflammatory effect through modulation of 
inflammatory cells.
Adenosine binds to several receptors such as A1, A2a, A2b, and A. 
ADORA 2a is highly expressed in synovium of RA patients receiving 
MTX, and SNPs in this gene are reported to influence adverse effect 
profile of MTX [42].
Hider et al. studied five SNPs in ADORA 2a in 309 RA patients 
(rs5760410, rs2298383, rs 3761422, rs2267076, and rs2236624) 
and found an association with GI adverse effects. The possible 
explanations were anti-proliferative effects in the gut and sensitization 
of chemoreceptors in the brain due to this polymorphism and could be 
alleviated by administration of folic acid and 5HT3 antagonists [43].
Wessels et al. reported favorable alleles for response as T allele of 
AMPD1, CC allele of ATIC C347G, and CC allele of ITPA C94A. Regarding 
toxicity, G allele of ATIC C347G was associated with GI AEs [44]. ATIC 
rs4673993 was assessed and reported as associated with low disease 
activity in the study [45].
Fig. 1: Genetic polymorphic alleles of different genes in methotrexate pathway with respect to its safety and efficacy. ABCB1: ATP-binding 
cassette proteins, MTX: Methotrexate, Chr: Chromosome number, RFC: Reduced folate carrier, MTHFR: Methylenetetrahydrofolate 
reductase, GGH: Gamma-glutamyl hydrolase, SHMT: Serine hydroxyl methyltransferase, ATIC: 5-aminoimidazole-4-carboxamide 
ribonucleotidetransformylase, MTRR: Methionine synthase reductase, MS: Methionine synthase, AMPD1: Adenosine monophosphate 
deaminase1, ITPA: Inosine triphosphate pyrophosphatase, FPGS: Foly-poly glutamyl synthase, AICAR: aminoimidazole-4-carboxamide 
ribonucleotide, TYMS or TSER: Thymidylate synthase, IMP: Inositol mono phosphate, ITP: Inositol triphosphate, DHFR: Dihydrofolate 
reductase, ADP: Adenosine diphosphate, ADA: Adenosine deaminase, SHMT: Serine hydroxyl methyltransferase
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Polygenetic analysis
Since several genes are associated with the absorption, distribution, 
metabolism, and elimination pathways of a drug, and several genes 
contribute to its pharmacokinetics and pharmacodynamics. Some 
of the studies were reported with polygenetic analysis, and some are 
highlighted in this regard.
Dervieux et al. studied the combined effect of RFC G80A, ATIC C347G, 
and TSER 2*/3* polymorphisms in 108 RA patients in relation with 
MTX-PG and efficacy. Favorable alleles were reported to be homozygotes 
of these polymorphisms (RFC-1 AA, ATIC 347GG, and TSER *2/*2) 
and a pharmacogenetic index was calculated. Patients having all 
the favorable alleles were reported to have increased RBC-MTX PG 
levels and improvement in disease activity (reduction in pain, tender 
joint count, swollen joint count, and physician’s global assessment) 
compared to noncarriers of all the genotypes. Pharmacogenetic and 
metabolite measurements are valuable tools in designing optimal 
drug therapy or individualized therapeutic strategies [2]. The same 
author in another study reported that the effect of GGH C401T, ATIC 
C347T, MTHFR A1298C, MTRR A2756G, and MS A66G combinations 
was studied by Dervieux et al. The risk alleles were identified as GGH 
401CC, ATIC 347GG, MTHFR 1298 AC/CC, MTRR 2756AA, and MS 66GG. 
These genotypes were found to be associated with CNS and GI adverse 
effects [46].
Wessels et al. studied the polygenetic effect of genes related to adenosine 
release and reported that the carriers of T allele of AMPD1, CC allele of 
ATIC C347G, and CC allele of ITPA C94A are good responders [44].
Weisman et al. studied the polygenic effects of MTHFR C677T, TYMS 
*2/*3, ATIC C34TG, and serine hydroxyl methyltransferase (SHMT) 
C1420T and found that the risk genotypes were TT alleles of MTHFR 
C677T (CNS adverse effects), CC alleles of SHMT C1420T (CNS adverse 
effects and alopecia), GG alleles of ATIC C34TG (GI adverse effects), and 
*2/*2 alleles of TYMS *2/*3 (alopecia) [26].
As a snapshot of the above-mentioned studies, the alleles of different 
genes and their relation to efficacy and susceptibility to toxicities of 
MTX are depicted in Fig. 1.
CONCLUSION
The application of pharmacogenetics from laboratory to personalized 
medicine is a tough task. The hurdles include identification of a 
subset of patients, economic constraints, and development of rapid 
techniques, ethical, legal, and moral implications. The potential genes 
influencing MTX efficacy or toxicity highlighted in this review insists 
the importance of pharmacogenetics. Identification of patients as good 
responders and segregating those susceptible to adverse effects could 
improve patient compliance. Although the studies have different results, 
the contributing reasons include lack of replication sets, inconsistent 
sample size, difference in parameters of measurement of drug toxicity, 
and efficacy. In addition, the genetic markers could be influenced by 
environmental factors such as diet-related folic acid intake. Application 
of pharmacogenetics as a right drug to the right person at the right 
time still has to go a long way to hit the nail of personalized medicine. 
In Indian scenario, only few studies are performed in relation to MTX 
in RA, and more prospective studies are essential to improve the 
therapeutic outcome.
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